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Interstitial lung disease (ILD) is the most severe extra-articular manifestation of rheumatoid arthritis 
(RA). Although it is responsible of 10-20% of all RA mortality, no controlled studies are available 
for the treatment of RA-ILD and its therapeutic approach is still debated. 
 
Aims 
In this study, we analysed the evolution of ILD in a population of RA patients treated with tocilizumab 
(TCZ).   
 
Methods 
In this national multicenter study, we retrospectively collected patients with RA-ILD treated with at 
least one dose of TCZ. For each patient, disease activity and serological data were evaluated. 
Moreover, we analysed the evolution of high-resolution computed tomography (HRCT) and 




Twenty-eight RA-ILD patients were identified (females/males 18/10, mean age 61.6 years), with a 
mean follow-up for TCZ therapy of 30 months. At the end of follow-up, FVC remained stable in 14 
patients (56%), improved in 5 (20%) and worsened in 6 (24%). DLCO remained stable in 14 patients 
(56%), improved in 5 (20%) and worsened in 6 (24%), even though in 3 patients DLCO and FVC 
showed an opposite trend. 
HRCT remained stable in the majority of cases (25), worsened in 2 patients with a usual interstitial 
pneumonia pattern, improved in only one case with a nonspecific interstitial pneumonia pattern.  
 
Conclusions 
The management of RA-ILD patients remains a critical unmet need. TCZ demonstrated a good safety 
profile in patients with RA-ILD and a potential effect on the stabilization of the lung involvement. 
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1. Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by synovial joint swelling 
and tenderness, with progressive disability and joint destruction1.  
The interstitial lung disease (ILD) is the most severe extra-articular manifestation of RA, with impact 
on both therapeutic strategy and overall prognosis and survival2. 
About 10% of the RA population develops a clinically significant ILD that is responsible for 
decreased quality of life and progressive chronic disability, but also of 10-20% of all mortality 
associated to the disease, with a mean survival of 5-8 years3-6. 
Although both genetic and environmental factors have been investigated, the pathogenesis of RA-
associated ILD (RA-ILD) remains unclear 7-8.  
Moreover, the majority of conventional and biologic diseases modifying anti-rheumatic drugs 
(DMARDs) have been associated to the development or progression of ILD9-10. 
For these reasons, since no controlled studies are available, the therapeutic approach to RA-ILD is 
still debated and often empirical7, 11-13. Some limited reports have evaluated the safety and the efficacy 
of tocilizumab (TCZ), a humanized anti-interleukin 6 (IL6) antibody, in the treatment of patients with 
RA-ILD14-15. 
In this retrospective study, we analysed the evolution of ILD in a population of RA patients treated 
with TCZ.   
 
2. Patients and methods  
In a national multicenter study, we retrospectively collected patients with ILD associated to RA 
treated with TCZ. All RA patients attending the Rheumatology Units of 6 Italian centers after 2008 
and treated with TCZ for at least 6 months were retrospectively evaluated to identify patients with 
ILD.  
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RA was diagnosed according to the 1987 or 2010 classification criteria depending on the year of 
diagnosis16, 17. The study was approved by the local Institutional Review Board. 
The different patterns of interstitial lung involvement, defined by pulmonary biopsy or chest high 
resolution computer tomography (HRCT), were classified according to the standardized criteria of 
the American Thoracic Society/European Respiratory Society International Multidisciplinary 
Consensus Classification of the Idiopathic Interstitial Pneumonias18 as follows: 1) definite or probable 
usual interstitial pneumonia (UIP), 2) non-specific interstitial pneumonia (NSIP); and 3) organizing 
pneumonia (OP) and mixed patterns.  
RF was determined by nephelometry; anti-cyclic citrullinated peptides antibodies (ACPA) were 
detected by standard commercial enzyme-linked immunosorbent assays (ELISA).  
The results of pulmonary function tests (PFT) were expressed as percentages of the predicted value 
of each parameter and corrected for age, gender and height. Pulmonary function was considered as 
abnormal if forced vital capacity (FVC) was <80% of predicted values. Single-breath diffusing 
capacity of the lung for carbon monoxide (DLCO-SB) and DLCO adjusted by the alveolar volume 
(DLCO-VA) were used to assess gas transfer. The last HRCT and the last PFT performed before 
starting TCZ were recorded as baseline. 
 
2.1 Outcome Variables  
A variation of 10% of FVC or DLCO compared to baseline was considered clinically significant19. 
Improvement, worsening or stability of HRCT was centrally evaluated in a blinded manner by an 
experienced thoracic radiologist (GDC). PFTs were collected at baseline and periodically assessed 
and for all patients was recorded the last available value (within 3 months from the end of follow-
up). All patients but one repeated HRCT at the end of follow-up.  
  
2.2 Statistical Analysis  
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Results were expressed as median and interquartile range (IQR). Continuous variables were compared 
using unpaired or paired nonparametric tests (Mann Whitney or Wilcoxon test, respectively). A p 
value less than 0.05 was considered significant. Statistical analyses were performed using the SPSS 
statistical software, version 17.0 (SPSS Inc., Chicago, IL, USA)20. 
 
3. Results  
We included 28 RA-ILD patients (18 females and 10 males, median age 64, IQR 15) treated with 
TCZ. The drug was administered at the standard dose, both intravenous (8 mg/kg every 4 weeks) and 
subcutaneously (162 mg weekly). For all patients, HRCT was available in the previous 12 months 
before the beginning and at the end of the therapy with TCZ, while PFTs were available in 25/28 
patients.  
Baseline characteristics of RA-ILD patients included in the study are summarized in Table 1.  
The median follow-up was 30 months (range 6-90). All patients were positive for RF and all but 2 for 
ACPA.  
An UIP pattern was described in 14/28 patients (50%), while a NSIP pattern was identified in other 
13 patients. In the last case a combined pattern pulmonary fibrosis and emphysema was recorded. 
All patients experienced therapies with synthetic or biologic DMARDs before TCZ. Twenty-five 
patients (89.3%) have been previously treated with methotrexate (MTX) and 10 with leflunomide 
(37%); among biologic DMARDs, 10 patients (37%) experienced a therapy with TNF inhibitors, 7 
with rituximab (25.9%) and 3 with abatacept (10.7%). 
Twenty-three patients taken TCZ as monotherapy, while in 5 patients TCZ was associated to MTX; 
on the other hand, 20 patients were treated with a low dose of prednisone (5 mg daily or equivalent). 
All patients but 3 were treated with subcutaneous TCZ, and 6 patients were switched from intravenous 
to subcutaneous route of administration.  
The evolution of lung function and radiology are summarized in Figure 1. 
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PFTs were available at baseline and at the end of the follow-up in 25 patients. After a median follow-
up of 30 months, FVC remained stable in 14 patients (56%), improved in 5 (20%) and worsened in 6 
(24%). Mean FVC was stable during follow-up (99%, IQR 27 at baseline and 96%, IQR 26 at the end 
of follow-up). 
DLCO showed a similar trend, remaining stable in 14 patients (56%), improving in 5 (20%) and 
worsening in 6 (24%), even though in 3 patients DLCO and FVC showed an opposite trend. Also 
mean DLCO remained stable during follow-up (58.5%, IQR 23 at baseline and 57%, IQR 31.5 at the 
end of follow-up). 
HRCT was performed at the end of the follow-up in all 28 patients, it was stable in 25 cases, worsened 
in 2 and improved in the latter. The worsening was recorded in patients with UIP pattern, while the 
only case of improvement was observed in a patient with NSIP pattern.  
No differences were recorded according to the duration of follow-up neither to the previous therapies. 
During the follow-up period, TCZ was withdrawn in 6/28 patients: for inefficacy in 3 cases and for 
adverse events in the other 3 (no adverse events were correlated to the treatment). No withdrawals 
were recorded for a worsening of ILD or for infections. 
 
4. Discussion 
In our study we evaluated the efficacy and the safety of TCZ in a retrospective cohort of patients 
affected by RA-ILD, showing a good safety and efficacy. The treatment of these patients is 
challenging, due to the possible role of DMARDs in the progression of the disease and in the 
development of acute exacerbation (AE). In fact, both MTX and leflunomide have been associated to 
ILD progression and development; recently, Conway demonstrated a mild increased risk of 
respiratory adverse events (but not ILD) in RA patients treated with MTX compared with other 
conventional and biologic DMARDs21. 
Moreover, some Authors described a possible class effect of all anti-tumour necrosis factor inhibitors 
(TNFi) in the new onset or exacerbation of ILD secondary to RA22-29.  Perez-Alvarez and colleagues 
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[27] and the British Society of Rheumatology has specifically cautioned prescribing TNFi to patients 
with RA-ILD for the supposed increased risk of exacerbation of the ILD30.  
Nakashita didn’t observe an increase of the prevalence of ILD progression in patients with TCZ and 
abatacept, whereas a prevalence of 3% of new ILD appearance and 24% of ILD worsening were 
described in TNFi users24, 29, 31. On the other side, Curtis et al. found no significant differences in the 
risk of ILD incidence and its related complications between patients exposed to tocilizumab, 
rituximab, or abatacept compared with TNFi therapies32. Moreover, some case reports have been 
reported about acute worsening of pre-existing RA-ILD in patients treated with TCZ33, 34. 
Despite the lack of evidences, the use of MTX is poorly indicated in patients with RA-ILD35-37. In 
this regard, TCZ could represent a possible safe drug in these patients, considering its efficacy in RA 
also as monotherapy38.  
In our population the majority of the patients showed a stability of pulmonary function and about 
20% showed an improvement of PFTs and less than a quarter of patients showed a deterioration of 
lung function. At the same time, only 2/28 patients showed a worsening of HRCT. 
On the whole TCZ demonstrated a good safety profile in patients with RA-ILD and a good efficacy 
on the stabilization of the lung involvement14, 15. In small case series, other Authors observed similar 
efficacy in RA-ILD patients treated with other biologic DMARDs. In particular, Md Yusof showed 
the improvement or the stability of ILD in 30/44 RA patients treated with rituximab, however 
describing a high number of infectious adverse events39; more recently, Fernández-Díaz et al 
described a high rate of improvement of ILD in 63 RA patients treated with abatacept with or without 
conventional DMARDS40. Data on abatacept were confirmed in 55 Japanese RA-ILD patients, 
despite the Authors observed a deterioration of lung function in patients treated with a combination 
therapy with MTX41. Finally, no reports have been reported until now about possible involvement in 
ILD appearance or deterioration for the Janus Kinases inhibitors42, 43.   
We cannot exclude that some biologic DMARDs, such as TCZ, abatacept, RTX, poorly influence the 
natural clinical history of ILD and our results, in line with recent literature data, could reflect the 
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natural evolution of lung involvement in RA. It should be essential, to minimize the risk of 
progression and acute exacerbation of ILD, reduce the risk of infection, providing the available 
vaccinations to all patients. 
The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective 
controlled studies, in patients with RA-ILD should be preferred biologic DMARDs, namely IL-6 
inhibitors, abatacept, and probably Janus kinases inhibitors, that have demonstrated a good safety 
profile in this specific population3, 11, 15, 42, 43. 
 
5. Conclusions 
In conclusion, despite the low number of patients investigated, TCZ should be considered a possible 
therapeutic option in patients with RA-ILD. Despite increasing data tend to exclude a role for MTX 
in development and progression of ILD44, the possibility to use TCZ in monotherapy without a 
significant loss of efficacy35 allows us to use this drug also in cases with ILD and high articular 
disease activity where the use of MTX is poorly recommended. 
Finally, an early diagnosis of ILD in RA patients is mandatory to understand the natural history of 
ILD, its possible predictive factors, and to evaluate the real involvement of some DMARDs, such as 
MTX, in the development and progression of this severe extra-articular complication45. 
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Figure 1. Evolution of lung function and radiology during follow-up. 
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Table 1. Demographic, clinical and serological features of patients at baseline 
    
Median age   64 (15) 




Disease duration 11.5 (13) 
ILD duration before TCZ therapy (months)  12 (34) 
Follow-up (months)  30 (44) 
    
Rheumatoid factor 28 (100%) 
ACPA 26 (92.8%) 
    
HRCT pattern  
 
 UIP  14 (50%) 
 NSIP  13 (46.5%) 




Forced vital capacity (%) 99 (27) 
Diffusion lung CO (%)  58.5 (23) 
  
  
Use of cDMARDs before TCZ  28 (100%) 
Mehotrexate  25 (89.3%) 
Leflunomide  10 (37%) 
TNFalpha inhibitors  10 (37%) 
Rituximab  7 (25.9%) 
Abatacept  2 (7.4%) 
   
TCZ mono-therapy  23 (82.1%) 
TCZ + methotrexate  5 (17.8%) 
Corticosteroids   20 (71.4%) 
Continuous data are reported as median (IQR).   
ACPA: anti-cyclic citrullinated peptides antibodies, UIP: usual interstitial pneumonia, NSIP: nonspecific interstitial 
pneumonia, CPFE: combined pulmonary fibrosis and emphysema, cDMARDs: conventional diseases modifying anti-
rheumatic drugs, TCZ: tocilizumab, IQR: interquartile range. 
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